{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:25:24Z","timestamp":1789892724889,"version":"4.0.1"},"reference-count":160,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2019.0119","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T06:40:30Z","timestamp":1550126430000},"source":"Crossref","is-referenced-by-count":56,"title":["Checkpoint Inhibitors"],"prefix":"10.3238","author":[{"given":"Lucie","family":"Heinzerling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"de Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe","family":"Hundorfean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"10.3238\/arztebl.2019.0119_ref1","doi-asserted-by":"crossref","unstructured":"Overman MJ, McDermott R, Leach JL, et al.: Nivolumab in patients with metastatic DNA mismatch repair deficient\/microsatellite instability\u2013high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18: 1182\u201391","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"10.3238\/arztebl.2019.0119_ref2","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377: 1345\u201356","DOI":"10.1056\/NEJMoa1709684"},{"key":"10.3238\/arztebl.2019.0119_ref3","doi-asserted-by":"crossref","unstructured":"Schachter J, Ribas A, Long GV, et al.: Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390: 1853\u201362","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"10.3238\/arztebl.2019.0119_ref4","doi-asserted-by":"crossref","unstructured":"Long GV, Atkinson V, Cebon JS, et al.: Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol 2017; 18: 1202\u201310","DOI":"10.1016\/S1470-2045(17)30428-X"},{"key":"10.3238\/arztebl.2019.0119_ref5","doi-asserted-by":"crossref","unstructured":"Postow MA, Sidlow R, Hellmann MD: Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 158\u201368","DOI":"10.1056\/NEJMra1703481"},{"key":"10.3238\/arztebl.2019.0119_ref6","doi-asserted-by":"crossref","unstructured":"Iwama S, De RA, Callahan MK, Slovin SF, Wolchok JD, Caturegli P: Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014; 6: 230ra45","DOI":"10.1126\/scitranslmed.3008002"},{"key":"10.3238\/arztebl.2019.0119_ref7","doi-asserted-by":"crossref","unstructured":"Dubin K, Callahan MK, Ren B, et al.: Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016; 7: 10391","DOI":"10.1038\/ncomms10391"},{"key":"10.3238\/arztebl.2019.0119_ref8","doi-asserted-by":"crossref","unstructured":"Chaput N, Lepage P, Coutzac C, et al.: Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017; 28: 1368\u201379","DOI":"10.1093\/annonc\/mdx108"},{"key":"10.3238\/arztebl.2019.0119_ref9","doi-asserted-by":"crossref","unstructured":"Hofmann L, Forschner A, Loquai C, et al.: Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190\u2013209","DOI":"10.1016\/j.ejca.2016.02.025"},{"key":"10.3238\/arztebl.2019.0119_ref10","doi-asserted-by":"crossref","unstructured":"Johnson DB, Balko JM, Compton ML, et al.: Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375: 1749\u201355","DOI":"10.1056\/NEJMoa1609214"},{"key":"10.3238\/arztebl.2019.0119_ref11","doi-asserted-by":"crossref","unstructured":"Heinzerling L, Ott PA, Hodi FS, et al.: Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 2016; 4: 50","DOI":"10.1186\/s40425-016-0152-y"},{"key":"10.3238\/arztebl.2019.0119_ref12","doi-asserted-by":"crossref","unstructured":"Bossart S, Thurneysen S, Rushing E, et al.: Case report: encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma. Oncologist 2017, 22: 749\u201353","DOI":"10.1634\/theoncologist.2016-0366"},{"key":"10.3238\/arztebl.2019.0119_ref13","doi-asserted-by":"crossref","unstructured":"Zimmer L, Goldinger SM, Hofmann L, et al.: Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 210\u201325","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"10.3238\/arztebl.2019.0119_ref14","doi-asserted-by":"crossref","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS: Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016; 2: 1607\u201316","DOI":"10.1001\/jamaoncol.2016.2453"},{"key":"10.3238\/arztebl.2019.0119_ref15","doi-asserted-by":"crossref","unstructured":"Hamid O, Robert C, Daud A, et al.: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134\u201344","DOI":"10.1056\/NEJMoa1305133"},{"key":"10.3238\/arztebl.2019.0119_ref16","doi-asserted-by":"crossref","unstructured":"Voskens CJ, Goldinger SM, Loquai C, et al.: The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8: e53745","DOI":"10.1371\/journal.pone.0053745"},{"key":"10.3238\/arztebl.2019.0119_ref17","doi-asserted-by":"crossref","unstructured":"O\u2019Day S, Weber JS, Wolchok JD, et al.: Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. J Clin Oncol 2011; 29: 15-suppl 8554.","DOI":"10.1200\/jco.2011.29.15_suppl.8554"},{"key":"10.3238\/arztebl.2019.0119_ref18","doi-asserted-by":"crossref","unstructured":"Schadendorf D, Wolchok JD, Hodi FS, et al.: Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse avents: a pooled analysis of randomized phase II and III trials. J Clin Oncol 2017; 35: 3807\u201314","DOI":"10.1200\/JCO.2017.73.2289"},{"key":"10.3238\/arztebl.2019.0119_ref19","doi-asserted-by":"crossref","unstructured":"Santini FC, Rizvi H, Wilkins O, et al.: Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol 2017; 35: 15_suppl 9012.","DOI":"10.1200\/JCO.2017.35.15_suppl.9012"},{"key":"10.3238\/arztebl.2019.0119_ref20","doi-asserted-by":"crossref","unstructured":"Horvat TZ, Adel NG, Dang TO, et al.: Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33: 3193\u20138","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"10.3238\/arztebl.2019.0119_ref21","doi-asserted-by":"crossref","unstructured":"Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P: Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 2016; 4: 36","DOI":"10.1186\/s40425-016-0139-8"},{"key":"10.3238\/arztebl.2019.0119_ref22","doi-asserted-by":"crossref","unstructured":"Dasanu CA, Jen T, Skulski R: Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. J Oncol Pharm Pract 2017; 23: 231\u20134","DOI":"10.1177\/1078155216635853"},{"key":"10.3238\/arztebl.2019.0119_ref23","doi-asserted-by":"crossref","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, et al.: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375\u201384","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"10.3238\/arztebl.2019.0119_ref24","doi-asserted-by":"crossref","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255\u201365","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"10.3238\/arztebl.2019.0119_ref25","doi-asserted-by":"crossref","unstructured":"Barlesi F, Vansteenkiste J, Spigel D, et al.: Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol 2018; 19: 1468\u201379","DOI":"10.1016\/S1470-2045(18)30673-9"},{"key":"10.3238\/arztebl.2019.0119_ref26","doi-asserted-by":"crossref","unstructured":"Hassel JC, Heinzerling L, Aberle J, et al.: Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 2017; 57: 36\u201349","DOI":"10.1016\/j.ctrv.2017.05.003"},{"key":"10.3238\/arztebl.2019.0119_ref27","doi-asserted-by":"crossref","unstructured":"O\u2019Kane GM, Lyons TG, Colleran GC, et al.: Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat 2014; 37: 757\u201360","DOI":"10.1159\/000368316"},{"key":"10.3238\/arztebl.2019.0119_ref28","doi-asserted-by":"crossref","unstructured":"Spain L, Diem S, Larkin J: Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44: 51\u201360","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"10.3238\/arztebl.2019.0119_ref29","doi-asserted-by":"crossref","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al.: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375: 1845\u201355","DOI":"10.1056\/NEJMoa1611299"},{"key":"10.3238\/arztebl.2019.0119_ref30","doi-asserted-by":"crossref","unstructured":"Tarhini AA, Lee SJ, Hodi FS, et al.: A phase III randomized study of adjuvant ipilimumab (3 or 10\u00a0mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms. J Clin Oncol 2017; 35: 15_suppl 9500.","DOI":"10.1200\/JCO.2017.35.15_suppl.9500"},{"key":"10.3238\/arztebl.2019.0119_ref31","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714\u201368","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"10.3238\/arztebl.2019.0119_ref32","doi-asserted-by":"crossref","unstructured":"Geukes Foppen MH, Rozeman EA, van Wilpe S, et al.: Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO open 2018; 3: e000278.","DOI":"10.1136\/esmoopen-2017-000278"},{"key":"10.3238\/arztebl.2019.0119_ref33","doi-asserted-by":"crossref","unstructured":"Hundorfean G, Atreya R, Agaimy A, et al.: Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis. Endoscopy 2012; 44: E78\u20139","DOI":"10.1055\/s-0031-1291603"},{"key":"10.3238\/arztebl.2019.0119_ref34","doi-asserted-by":"crossref","unstructured":"Lankes K, Hundorfean G, Harrer T, et al.: Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology 2016; 5: e1128611","DOI":"10.1080\/2162402X.2015.1128611"},{"key":"10.3238\/arztebl.2019.0119_ref35","doi-asserted-by":"crossref","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al.: Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl_4): iv119\u201342.","DOI":"10.1093\/annonc\/mdx225"},{"key":"10.3238\/arztebl.2019.0119_ref36","doi-asserted-by":"crossref","unstructured":"de Martin E, Michot JM, Papouin B, et al.: Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018; 68: 1181\u201390","DOI":"10.1016\/j.jhep.2018.01.033"},{"key":"10.3238\/arztebl.2019.0119_ref37","doi-asserted-by":"crossref","unstructured":"Sp\u00e4nkuch I, Gassenmaier M, Tampouri I, et al.: Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins. Eur J Cancer 2017; 81: 203\u20135","DOI":"10.1016\/j.ejca.2017.05.018"},{"key":"10.3238\/arztebl.2019.0119_ref38","doi-asserted-by":"crossref","unstructured":"Doherty GJ, Duckworth AM, Davies SE, et al.: Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open 2017; 2: e000268","DOI":"10.1136\/esmoopen-2017-000268"},{"key":"10.3238\/arztebl.2019.0119_ref39","doi-asserted-by":"crossref","unstructured":"Chmiel KD, Suan D, Liddle C, et al.: Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011; 29: e237\u201340","DOI":"10.1200\/JCO.2010.32.2206"},{"key":"10.3238\/arztebl.2019.0119_ref40","doi-asserted-by":"crossref","unstructured":"McGuire HM, Shklovskaya E, Edwards J, et al.: Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother 2018; 67: 563\u201373","DOI":"10.1007\/s00262-017-2107-7"},{"key":"10.3238\/arztebl.2019.0119_ref41","doi-asserted-by":"crossref","unstructured":"Uslu U, Agaimy A, Hundorfean G, Harrer T, Schuler G, Heinzerling L: Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. J Immunother 2015; 38: 212\u20135","DOI":"10.1097\/CJI.0000000000000081"},{"key":"10.3238\/arztebl.2019.0119_ref42","doi-asserted-by":"crossref","unstructured":"Eigentler TK, Hassel JC, Berking C, et al.: Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016; 45: 7\u201318","DOI":"10.1016\/j.ctrv.2016.02.003"},{"key":"10.3238\/arztebl.2019.0119_ref43","doi-asserted-by":"crossref","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al.: Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 173\u201382","DOI":"10.1001\/jamaoncol.2017.3064"},{"key":"10.3238\/arztebl.2019.0119_ref44","doi-asserted-by":"crossref","unstructured":"Changizzadeh PN, Mukkamalla SKR, Armenio VA: Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma. J Immunother Cancer 2017; 5: 97","DOI":"10.1186\/s40425-017-0303-9"},{"key":"10.3238\/arztebl.2019.0119_ref45","doi-asserted-by":"crossref","unstructured":"Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH: The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol 2018; 178: 175\u201382","DOI":"10.1530\/EJE-17-0810"},{"key":"10.3238\/arztebl.2019.0119_ref46","doi-asserted-by":"crossref","unstructured":"Lee H, Hodi FS, Giobbie-Hurder A, et al.: Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol Res 2017; 5: 1133\u201340 MEDLINE","DOI":"10.1158\/2326-6066.CIR-17-0208"},{"key":"10.3238\/arztebl.2019.0119_ref47","doi-asserted-by":"crossref","unstructured":"Hughes J, Vudattu N, Sznol M, et al.: Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015; 38: e55\u20137.","DOI":"10.2337\/dc14-2349"},{"key":"10.3238\/arztebl.2019.0119_ref48","doi-asserted-by":"crossref","unstructured":"Martin-Liberal J, Furness AJS, Joshi K, Peggs KS, Quezada SA, Larkin J: Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 2015; 64: 765\u20137","DOI":"10.1007\/s00262-015-1689-1"},{"key":"10.3238\/arztebl.2019.0119_ref49","doi-asserted-by":"crossref","unstructured":"Okamoto M, Okamoto M, Gotoh K, et al.: Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig 2016; 7: 915\u20138","DOI":"10.1111\/jdi.12531"},{"key":"10.3238\/arztebl.2019.0119_ref50","doi-asserted-by":"crossref","unstructured":"Gaudy C, Cl\u00e9vy Ć, Monestier S, et al.: Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 2015; 38: e182\u20133.","DOI":"10.2337\/dc15-1331"},{"key":"10.3238\/arztebl.2019.0119_ref51","doi-asserted-by":"crossref","unstructured":"Miyoshi Y, Ogawa O, Oyama Y: Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes. Tohoku J Exp Med 2016; 239: 155\u20138","DOI":"10.1620\/tjem.239.155"},{"key":"10.3238\/arztebl.2019.0119_ref52","doi-asserted-by":"crossref","unstructured":"Min L, Hodi FS, Giobbie-Hurder A, et al.: Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 2015; 21: 749\u201355","DOI":"10.1158\/1078-0432.CCR-14-2353"},{"key":"10.3238\/arztebl.2019.0119_ref53","doi-asserted-by":"crossref","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS: Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016; 2: 1607\u201316","DOI":"10.1001\/jamaoncol.2016.2453"},{"key":"10.3238\/arztebl.2019.0119_ref54","doi-asserted-by":"crossref","unstructured":"Naidoo J, Wang X, Woo KM, et al.: Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 2017; 35: 709\u201317","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"10.3238\/arztebl.2019.0119_ref55","doi-asserted-by":"crossref","unstructured":"Nishino M, Ramaiya NH, Awad MM, et al.: PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 2016; 22: 6051\u201360","DOI":"10.1158\/1078-0432.CCR-16-1320"},{"key":"10.3238\/arztebl.2019.0119_ref56","doi-asserted-by":"crossref","unstructured":"Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F: Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract 2017; 23: 620\u20134","DOI":"10.1177\/1078155216667635"},{"key":"10.3238\/arztebl.2019.0119_ref57","doi-asserted-by":"crossref","unstructured":"Montaudi\u00e9 H, Pradelli J, Passeron T, Lacour JP, Leroy S: Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol 2016; 176: 1060\u20133","DOI":"10.1111\/bjd.14808"},{"key":"10.3238\/arztebl.2019.0119_ref58","doi-asserted-by":"crossref","unstructured":"Suozzi KC, Stahl M, Ko CJ, et al.: Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep 2016; 2: 264\u20138","DOI":"10.1016\/j.jdcr.2016.05.002"},{"key":"10.3238\/arztebl.2019.0119_ref59","doi-asserted-by":"crossref","unstructured":"Jespersen H, Bjursten S, Ny L, Levin M: Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. Lancet Oncol 2018; 19: e327","DOI":"10.1016\/S1470-2045(18)30252-3"},{"key":"10.3238\/arztebl.2019.0119_ref60","doi-asserted-by":"crossref","unstructured":"Boutros C, Tarhini A, Routier E, et al.: Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; 13: 473\u201386","DOI":"10.1038\/nrclinonc.2016.58"},{"key":"10.3238\/arztebl.2019.0119_ref61","doi-asserted-by":"crossref","unstructured":"Vandiver JW, Singer Z, Harshberger C: Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. Target Oncol 2016; 11: 553\u20136","DOI":"10.1007\/s11523-016-0426-9"},{"key":"10.3238\/arztebl.2019.0119_ref62","doi-asserted-by":"crossref","unstructured":"Rizvi NA, Hellmann MD, Brahmer JR, et al.: Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34: 2969\u201379","DOI":"10.1200\/JCO.2016.66.9861"},{"key":"10.3238\/arztebl.2019.0119_ref63","doi-asserted-by":"crossref","unstructured":"Voskens C, Cavallaro A, Erdmann M, et al.: Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 2012; 30: e356\u20137.","DOI":"10.1200\/JCO.2011.41.4359"},{"key":"10.3238\/arztebl.2019.0119_ref64","doi-asserted-by":"crossref","unstructured":"Kaufman HL, Russell J, Hamid O, et al.: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17: 1374\u201385","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"10.3238\/arztebl.2019.0119_ref65","doi-asserted-by":"crossref","unstructured":"Escandon J, Peacock S, Trabolsi A, Thomas DB, Layka A, Lutzky J: Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J Immunother Cancer 2017; 5: 3","DOI":"10.1186\/s40425-016-0205-2"},{"key":"10.3238\/arztebl.2019.0119_ref66","doi-asserted-by":"crossref","unstructured":"Shirali AC, Perazella MA, Gettinger S: Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 2016; 68: 287\u201391","DOI":"10.1053\/j.ajkd.2016.02.057"},{"key":"10.3238\/arztebl.2019.0119_ref67","doi-asserted-by":"crossref","unstructured":"Jung K, Zeng X, Bilusic M: Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol 2016; 17: 188","DOI":"10.1186\/s12882-016-0408-2"},{"key":"10.3238\/arztebl.2019.0119_ref68","doi-asserted-by":"crossref","unstructured":"Fadel F, Karoui K El, Knebelmann B: Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361: 211\u20132","DOI":"10.1056\/NEJMc0904283"},{"key":"10.3238\/arztebl.2019.0119_ref69","doi-asserted-by":"crossref","unstructured":"Cortazar FB, Marrone KA, Troxell ML, et al.: Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016; 90: 638\u201347","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"10.3238\/arztebl.2019.0119_ref70","doi-asserted-by":"crossref","unstructured":"Kishi S, Minato M, Saijo A, et al.: IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med 2018; 57: 1259\u201363","DOI":"10.2169\/internalmedicine.9814-17"},{"key":"10.3238\/arztebl.2019.0119_ref71","doi-asserted-by":"crossref","unstructured":"L\u00e4ubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A: Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015; 3: 11","DOI":"10.1186\/s40425-015-0057-1"},{"key":"10.3238\/arztebl.2019.0119_ref72","doi-asserted-by":"crossref","unstructured":"Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L: Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy. J Immunother 2018; 41: 35\u20138","DOI":"10.1097\/CJI.0000000000000190"},{"key":"10.3238\/arztebl.2019.0119_ref73","doi-asserted-by":"crossref","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.: Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018; 71: 1755\u201364","DOI":"10.1016\/S0735-1097(18)31240-3"},{"key":"10.3238\/arztebl.2019.0119_ref74","doi-asserted-by":"crossref","unstructured":"Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Groh\u00e9 C: Drug-induced myocarditis after nivolumab treatment in a patient with PDL1-negative squamous cell carcinoma of the lung. Lung Cancer 2016; 99: 117\u20139","DOI":"10.1016\/j.lungcan.2016.06.025"},{"key":"10.3238\/arztebl.2019.0119_ref75","unstructured":"Heymans L, Mentzer D, Keller-Stanislawski B: Verdachtsf\u00e4lle unerw\u00fcnschter Reaktionen nach Checkpoint-Inhibitoren aus Deutschland. Bull Arzneimittelsicherheit 2016; 4: 11\u20138."},{"key":"10.3238\/arztebl.2019.0119_ref76","doi-asserted-by":"crossref","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB: Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018; 391: 933","DOI":"10.1016\/S0140-6736(18)30533-6"},{"key":"10.3238\/arztebl.2019.0119_ref77","doi-asserted-by":"crossref","unstructured":"Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S: Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med 2015; Article ID:\u00a0794842.","DOI":"10.1155\/2015\/794842"},{"key":"10.3238\/arztebl.2019.0119_ref78","doi-asserted-by":"crossref","unstructured":"Kushnir I, Wolf I: Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology 2017; 136: 49\u201351","DOI":"10.1159\/000447053"},{"key":"10.3238\/arztebl.2019.0119_ref79","doi-asserted-by":"crossref","unstructured":"Gibson R, Delaune J, Szady A, Markham M: Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep 2016; 2016. pii: bcr2016216228","DOI":"10.1136\/bcr-2016-216228"},{"key":"10.3238\/arztebl.2019.0119_ref80","doi-asserted-by":"crossref","unstructured":"Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR: Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 2015; 3: 4","DOI":"10.1186\/s40425-015-0048-2"},{"key":"10.3238\/arztebl.2019.0119_ref81","doi-asserted-by":"crossref","unstructured":"Arangalage D, Delyon J, Lermuzeaux M, et al.: Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 2017; 167: 683\u20134","DOI":"10.7326\/L17-0396"},{"key":"10.3238\/arztebl.2019.0119_ref82","doi-asserted-by":"crossref","unstructured":"John S, Antonia SJ, Rose TA, et al.: Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment. J Immunother Cancer 2017; 5: 54","DOI":"10.1186\/s40425-017-0258-x"},{"key":"10.3238\/arztebl.2019.0119_ref83","doi-asserted-by":"crossref","unstructured":"Belkhir R, Burel SL, Dunogeant L, et al.: Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 2017; 76: 1747\u201350","DOI":"10.1136\/annrheumdis-2017-211216"},{"key":"10.3238\/arztebl.2019.0119_ref84","doi-asserted-by":"crossref","unstructured":"Lidar M, Giat E, Garelick D, et al.: Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018; 17: 284\u20139","DOI":"10.1016\/j.autrev.2018.01.003"},{"key":"10.3238\/arztebl.2019.0119_ref85","doi-asserted-by":"crossref","unstructured":"de Velasco G, Bermas B, Choueiri TK: Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol 2016; 68: 556\u20137","DOI":"10.1002\/art.39406"},{"key":"10.3238\/arztebl.2019.0119_ref86","doi-asserted-by":"crossref","unstructured":"Chen Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB: Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol (Phila) 2018; 56: 667\u201371","DOI":"10.1080\/15563650.2017.1401079"},{"key":"10.3238\/arztebl.2019.0119_ref87","doi-asserted-by":"crossref","unstructured":"Sakai K, Mochizuki H, Mochida K, Shiomi K, Amano M, Nakazato M: A case of nivolumab-induced severe mononeuropathy multiplex and rhabdomyolysis. Case Rep Med 2017; Article ID:1093858.","DOI":"10.1155\/2017\/1093858"},{"key":"10.3238\/arztebl.2019.0119_ref88","doi-asserted-by":"crossref","unstructured":"Sheik Ali S, Goddard AL, Luke JJ, et al.: Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatology 2015; 151: 195\u20139","DOI":"10.1001\/jamadermatol.2014.2233"},{"key":"10.3238\/arztebl.2019.0119_ref89","doi-asserted-by":"crossref","unstructured":"Chan MMK, Kefford RF, Carlino M, Clements A, Manolios N: Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 2015; 38: 37\u20139","DOI":"10.1097\/CJI.0000000000000060"},{"key":"10.3238\/arztebl.2019.0119_ref90","doi-asserted-by":"crossref","unstructured":"Goldstein BL, Gedmintas L, Todd DJ: Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 2014; 66: 768\u20139","DOI":"10.1002\/art.38282"},{"key":"10.3238\/arztebl.2019.0119_ref91","doi-asserted-by":"crossref","unstructured":"Kim ST, Tayar J, Trinh VA, et al.: Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis 2017; 76: 2061\u20134","DOI":"10.1136\/annrheumdis-2017-211560"},{"key":"10.3238\/arztebl.2019.0119_ref92","doi-asserted-by":"crossref","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.: Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 2017; 73: 1\u20138","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"10.3238\/arztebl.2019.0119_ref93","doi-asserted-by":"crossref","unstructured":"Heinzerling L, Goldinger SM: A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol 2017; 29: 136\u201344","DOI":"10.1097\/CCO.0000000000000358"},{"key":"10.3238\/arztebl.2019.0119_ref94","doi-asserted-by":"crossref","unstructured":"Conry RM, Sullivan JC, Nabors LB III:. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res 2015; 3: 598\u2013601","DOI":"10.1158\/2326-6066.CIR-15-0035"},{"key":"10.3238\/arztebl.2019.0119_ref95","doi-asserted-by":"crossref","unstructured":"Carl D, Grullich C, Hering S, Schabet M: Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC Res Notes 2015; 8: 316","DOI":"10.1186\/s13104-015-1283-9"},{"key":"10.3238\/arztebl.2019.0119_ref96","doi-asserted-by":"crossref","unstructured":"Stein MK, Summers BB, Wong CA, Box HL, Cleveland KO: Meningoencephalitis following ipilimumab administration in metastatic melanoma. Am J Med Sci 2015; 350: 512\u20133","DOI":"10.1097\/MAJ.0000000000000584"},{"key":"10.3238\/arztebl.2019.0119_ref97","doi-asserted-by":"crossref","unstructured":"Williams TJ, Benavides DR, Patrice KA, et al.: Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016; 73: 928\u201333","DOI":"10.1001\/jamaneurol.2016.1399"},{"key":"10.3238\/arztebl.2019.0119_ref98","doi-asserted-by":"crossref","unstructured":"Tchapyjnikov D, Borst AJ: Immune-related neurological symptoms in an adolescent patient receiving the checkpoint inhibitor nivolumab. J Immunother 2017; 40: 286\u20138","DOI":"10.1097\/CJI.0000000000000177"},{"key":"10.3238\/arztebl.2019.0119_ref99","doi-asserted-by":"crossref","unstructured":"Larkin J, Chmielowski B, Lao CD, et al.: Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 2017; 22: 709\u201318","DOI":"10.1634\/theoncologist.2016-0487"},{"key":"10.3238\/arztebl.2019.0119_ref100","doi-asserted-by":"crossref","unstructured":"Schneider S, Potthast S, Komminoth P, Schwegler G, B\u00f6hm S: PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol 2017; 10: 473\u20138","DOI":"10.1159\/000477162"},{"key":"10.3238\/arztebl.2019.0119_ref101","doi-asserted-by":"crossref","unstructured":"Leitinger M, Varosanec MV, Pikija S, et al.: Fatal necrotizing encephalopathy after treatment with nivolumab for squamous non-small cell lung cancer: case report and review of the literature. Front Immunol 2018; 9: 108","DOI":"10.3389\/fimmu.2018.00108"},{"key":"10.3238\/arztebl.2019.0119_ref102","doi-asserted-by":"crossref","unstructured":"Salam S, Lavin T, Turan A: Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep 2016; 2016, pii: bcr2016215012.","DOI":"10.1136\/bcr-2016-215012"},{"key":"10.3238\/arztebl.2019.0119_ref103","doi-asserted-by":"crossref","unstructured":"Yang JC, Hughes M, Kammula U, et al.: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825\u201330","DOI":"10.1097\/CJI.0b013e318156e47e"},{"key":"10.3238\/arztebl.2019.0119_ref104","doi-asserted-by":"crossref","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S: Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014; 16: 589\u201393","DOI":"10.1093\/neuonc\/nou001"},{"key":"10.3238\/arztebl.2019.0119_ref105","doi-asserted-by":"crossref","unstructured":"Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW: Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 2014; 344: 229\u201331","DOI":"10.1016\/j.jns.2014.06.023"},{"key":"10.3238\/arztebl.2019.0119_ref106","doi-asserted-by":"crossref","unstructured":"Abdallah AO, Herlopian A, Ravilla R, et al.: Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature. J Oncol Pharm Pract 2016; 22: 537\u201342","DOI":"10.1177\/1078155215572932"},{"key":"10.3238\/arztebl.2019.0119_ref107","doi-asserted-by":"crossref","unstructured":"Tarhini A: Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013; 2013: 857519.","DOI":"10.1155\/2013\/857519"},{"key":"10.3238\/arztebl.2019.0119_ref108","doi-asserted-by":"crossref","unstructured":"Thaipisuttikul I, Chapman P, Avila EK: Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother 2015; 38: 77\u20139","DOI":"10.1097\/CJI.0000000000000070"},{"key":"10.3238\/arztebl.2019.0119_ref109","doi-asserted-by":"crossref","unstructured":"Maurice C, Schneider R, Kiehl TR, et al.: Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res 2015; 3: 1299\u2013302","DOI":"10.1158\/2326-6066.CIR-15-0141"},{"key":"10.3238\/arztebl.2019.0119_ref110","doi-asserted-by":"crossref","unstructured":"Makarious D, Horwood K, Coward JIG: Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 2017; 82: 128\u201336","DOI":"10.1016\/j.ejca.2017.05.041"},{"key":"10.3238\/arztebl.2019.0119_ref111","doi-asserted-by":"crossref","unstructured":"Murphy KP, Kennedy MP, Barry JE, O\u2019Regan KN, Power DG: New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat 2014; 37: 351\u20133","DOI":"10.1159\/000362614"},{"key":"10.3238\/arztebl.2019.0119_ref112","doi-asserted-by":"crossref","unstructured":"Spain L, Walls G, Julve M, et al.: Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 2017; 28: 377\u201385.","DOI":"10.1093\/annonc\/mdw558"},{"key":"10.3238\/arztebl.2019.0119_ref113","doi-asserted-by":"crossref","unstructured":"Kumar B, Ballas Z: Adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 1164.","DOI":"10.1056\/NEJMc1801663"},{"key":"10.3238\/arztebl.2019.0119_ref114","doi-asserted-by":"crossref","unstructured":"Belum VR, Benhuri B, Postow MA, et al.: Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12\u201325","DOI":"10.1016\/j.ejca.2016.02.010"},{"key":"10.3238\/arztebl.2019.0119_ref115","doi-asserted-by":"crossref","unstructured":"Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP: Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28: 254\u201363","DOI":"10.1097\/CCO.0000000000000290"},{"key":"10.3238\/arztebl.2019.0119_ref116","doi-asserted-by":"crossref","unstructured":"Abdel-Rahman O, El Halawani H, Fouad M: Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Futur Oncol 2015; 11: 2471\u201384","DOI":"10.2217\/fon.15.118"},{"key":"10.3238\/arztebl.2019.0119_ref117","doi-asserted-by":"crossref","unstructured":"Carlos G, Anforth R, Chou S, Clements A, Fernandez-Pe\u00f1as P: A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 2015; 25: 265\u20138","DOI":"10.1097\/CMR.0000000000000155"},{"key":"10.3238\/arztebl.2019.0119_ref118","doi-asserted-by":"crossref","unstructured":"Naidoo J, Schindler K, Querfeld C, et al.: Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016; 4: 383\u20139","DOI":"10.1158\/2326-6066.CIR-15-0123"},{"key":"10.3238\/arztebl.2019.0119_ref119","doi-asserted-by":"crossref","unstructured":"Jour G, Glitza IC, Ellis RM, et al.: Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 2016; 43: 688\u201396","DOI":"10.1111\/cup.12717"},{"key":"10.3238\/arztebl.2019.0119_ref120","doi-asserted-by":"crossref","unstructured":"Anastasopoulou A, Papaxoinis G, Diamantopoulos P, et al.: Bullous pemphigoid-like skin lesions and overt eosinophilia in a patient with melanoma treated with nivolumab: case report and review of the literature. J Immunother 2018; 41: 164\u20137","DOI":"10.1097\/CJI.0000000000000210"},{"key":"10.3238\/arztebl.2019.0119_ref121","doi-asserted-by":"crossref","unstructured":"Mochel MC, Ming ME, Imadojemu S, et al.: Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol 2016; 43: 787\u201391","DOI":"10.1111\/cup.12735"},{"key":"10.3238\/arztebl.2019.0119_ref122","doi-asserted-by":"crossref","unstructured":"Goldinger SM, Stieger P, Meier B, et al.: Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 2016; 22: 4023\u20139","DOI":"10.1158\/1078-0432.CCR-15-2872"},{"key":"10.3238\/arztebl.2019.0119_ref123","doi-asserted-by":"crossref","unstructured":"Hwang SJE, Carlos G, Wakade D, et al.: Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74: 455\u201361","DOI":"10.1016\/j.jaad.2015.10.029"},{"key":"10.3238\/arztebl.2019.0119_ref124","doi-asserted-by":"crossref","unstructured":"Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T: Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol 2015; 151: 797\u20139","DOI":"10.1001\/jamadermatol.2015.0249"},{"key":"10.3238\/arztebl.2019.0119_ref125","doi-asserted-by":"crossref","unstructured":"Bonigen J, Raynaud-Donzel C, Hureaux J, et al.: Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol 2017; 31: e254\u20137.","DOI":"10.1111\/jdv.14011"},{"key":"10.3238\/arztebl.2019.0119_ref126","doi-asserted-by":"crossref","unstructured":"Schmutz JL: [Psoriasis and psoriatic arthritis induced by nivolumab (Opdivo\u00ae)]. Ann Dermatol Venereol 2016; 143: 881\u20132.","DOI":"10.1016\/j.annder.2016.08.003"},{"key":"10.3238\/arztebl.2019.0119_ref127","doi-asserted-by":"crossref","unstructured":"Mutgi KAJ, Milhem M, Swick BL, Liu V: Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma. JAAD Case Rep 2016; 2: 343\u20135","DOI":"10.1016\/j.jdcr.2016.06.012"},{"key":"10.3238\/arztebl.2019.0119_ref128","doi-asserted-by":"crossref","unstructured":"Uemura M, Fa\u2018ak F, Haymaker C, et al.: A case report of Grover\u2019s disease from immunotherapy - a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer 2017; 5: 7","DOI":"10.1186\/s40425-017-0208-7"},{"key":"10.3238\/arztebl.2019.0119_ref129","doi-asserted-by":"crossref","unstructured":"Burillo-Martinez S, Morales-Raya C, Prieto-Barrios M, Rodriguez-Peralto JL, Ortiz-Romero PL: Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum. JAMA Dermatol 2017; 153: 721\u20132","DOI":"10.1001\/jamadermatol.2017.0581"},{"key":"10.3238\/arztebl.2019.0119_ref130","doi-asserted-by":"crossref","unstructured":"Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, et al.: Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy - report of 2 patients. J Cutan Pathol 2017; 44: 1080\u20136.","DOI":"10.1111\/cup.13044"},{"key":"10.3238\/arztebl.2019.0119_ref131","doi-asserted-by":"crossref","unstructured":"Diem S, Keller F, R\u00fcesch R, et al.: Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy? J Immunother 2016; 39: 379\u201382.","DOI":"10.1097\/CJI.0000000000000143"},{"key":"10.3238\/arztebl.2019.0119_ref132","doi-asserted-by":"crossref","unstructured":"Nguyen AT, Elia M, Materin MA, Sznol M, Chow J: Cyclosporine for dry eye associated with nivolumab: a case progressing to cornealperforation. Cornea 2016; 35: 399\u2013401","DOI":"10.1097\/ICO.0000000000000724"},{"key":"10.3238\/arztebl.2019.0119_ref133","doi-asserted-by":"crossref","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, et al.: Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017; 76: 43\u201350","DOI":"10.1136\/annrheumdis-2016-209595"},{"key":"10.3238\/arztebl.2019.0119_ref134","doi-asserted-by":"crossref","unstructured":"Wilson MA, Guld K, Galetta S, et al.: Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 2016; 4: 66","DOI":"10.1186\/s40425-016-0170-9"},{"key":"10.3238\/arztebl.2019.0119_ref135","doi-asserted-by":"crossref","unstructured":"Comito RR, Badu LA, Forcello N: Nivolumab-induced aplastic anemia: a case report and literature review. J Oncol Pharm Pract 2019; 25: 221\u20135","DOI":"10.1177\/1078155217726159"},{"key":"10.3238\/arztebl.2019.0119_ref136","doi-asserted-by":"crossref","unstructured":"Palla AR, Kennedy D, Mosharraf H, Doll D: Autoimmune hemolytic anemia as a complication of nivolumab therapy. Case Rep Oncol 2016; 9: 691\u20137","DOI":"10.1159\/000452296"},{"key":"10.3238\/arztebl.2019.0119_ref137","doi-asserted-by":"crossref","unstructured":"Le Roy A, Kempf E, Ackermann F, et al.: Two cases of immune thrombocytopenia associated with pembrolizumab. Eur J Cancer 2016; 54: 172\u20134","DOI":"10.1016\/j.ejca.2015.10.073"},{"key":"10.3238\/arztebl.2019.0119_ref138","doi-asserted-by":"crossref","unstructured":"Pf\u00f6hler C, Eichler H, Burgard B, Kreck\u00e9 N, M\u00fcller CSL, Vogt T: A case of immune thrombocytopenia as a rare side effect of an immunotherapy with PD1-blocking agents for metastatic melanoma. Transfus Med Hemother 2017; 44: 426\u20138.","DOI":"10.1159\/000479237"},{"key":"10.3238\/arztebl.2019.0119_ref139","doi-asserted-by":"crossref","unstructured":"Turgeman I, Wollner M, Hassoun G, Bonstein L, Bar-Sela G: Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anticancer Drugs 2017; 28: 811\u20134","DOI":"10.1097\/CAD.0000000000000520"},{"key":"10.3238\/arztebl.2019.0119_ref140","doi-asserted-by":"crossref","unstructured":"Tabchi S, Weng X, Blais N: Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer 2016; 99: 123\u20136","DOI":"10.1016\/j.lungcan.2016.06.026"},{"key":"10.3238\/arztebl.2019.0119_ref141","doi-asserted-by":"crossref","unstructured":"Michot JM, Bigenwald C, Champiat S, et al.: Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139\u201348","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"10.3238\/arztebl.2019.0119_ref142","doi-asserted-by":"crossref","unstructured":"Tardy MP, Gastaud L, Boscagli A, Peyrade F, Gallamini A, Thyss A: Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report. Hematol Oncol 2017; 35: 875\u20137","DOI":"10.1002\/hon.2338"},{"key":"10.3238\/arztebl.2019.0119_ref143","doi-asserted-by":"crossref","unstructured":"Del Castillo M, Romero FA, Arg\u00fcello E, Kyi C, Postow MA, Redelman-Sidi G: The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 2016; 63: 1490\u20133","DOI":"10.1093\/cid\/ciw539"},{"key":"10.3238\/arztebl.2019.0119_ref144","doi-asserted-by":"crossref","unstructured":"Shiuan E, Beckermann KE, Ozgun A, et al.: Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 2017; 5: 8","DOI":"10.1186\/s40425-017-0210-0"},{"key":"10.3238\/arztebl.2019.0119_ref145","doi-asserted-by":"crossref","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al.: Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. J Clin Oncol 2017; 28: 368\u201376.","DOI":"10.1093\/annonc\/mdw443"},{"key":"10.3238\/arztebl.2019.0119_ref146","doi-asserted-by":"crossref","unstructured":"Gutzmer R, Koop A, Meier F, et al.: Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017; 75: 24\u201332","DOI":"10.1016\/j.ejca.2016.12.038"},{"key":"10.3238\/arztebl.2019.0119_ref147","doi-asserted-by":"crossref","unstructured":"Johnson DB, Sullivan RJ, Ott PA, et al.: Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016; 2: 234\u201340","DOI":"10.1001\/jamaoncol.2015.4368"},{"key":"10.3238\/arztebl.2019.0119_ref148","doi-asserted-by":"crossref","unstructured":"Gettings EJ, Hackett CT, Scott TF: Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler 2015; 21: 670","DOI":"10.1177\/1352458514549403"},{"key":"10.3238\/arztebl.2019.0119_ref149","doi-asserted-by":"crossref","unstructured":"Kittai AS, Oldham H, Cetnar J, Taylor M: Immune checkpoint inhibitors in organ transplant patients. J Immunother 2017; 40: 277\u201381","DOI":"10.1097\/CJI.0000000000000180"},{"key":"10.3238\/arztebl.2019.0119_ref150","doi-asserted-by":"crossref","unstructured":"Qin R, Salama AK: Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus. Melanoma Manag 2015; 2: 311\u20134","DOI":"10.2217\/mmt.15.27"},{"key":"10.3238\/arztebl.2019.0119_ref151","doi-asserted-by":"crossref","unstructured":"Friend BD, Venick RS, McDiarmid SV, et al.: Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer 2017; doi: 10.1002\/pbc.26682","DOI":"10.1002\/pbc.26682"},{"key":"10.3238\/arztebl.2019.0119_ref152","doi-asserted-by":"crossref","unstructured":"Tio M, Rai R, Ezeoke OM, et al.: Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV, and hepatitis B\/C infection. Eur J Cancer 2018; 104: 137\u201344","DOI":"10.1016\/j.ejca.2018.09.017"},{"key":"10.3238\/arztebl.2019.0119_ref153","doi-asserted-by":"crossref","unstructured":"Munker S, de Toni EN: Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J 2018; 6: 970\u20133","DOI":"10.1177\/2050640618774631"},{"key":"10.3238\/arztebl.2019.0119_ref154","doi-asserted-by":"crossref","unstructured":"Winkler JK, Gutzmer R, Bender C, et al.: Safe administration of an anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature. J Immunother 2017; 40: 341\u20134","DOI":"10.1097\/CJI.0000000000000188"},{"key":"10.3238\/arztebl.2019.0119_ref155","doi-asserted-by":"crossref","unstructured":"Herz S, H\u00f6fer T, Papapanagiotou M, et al.: Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer 2016; 67: 66\u201372","DOI":"10.1016\/j.ejca.2016.07.026"},{"key":"10.3238\/arztebl.2019.0119_ref156","doi-asserted-by":"crossref","unstructured":"Ong M, Ibrahim AM, Bourassa-Blanchette S, Canil C, Fairhead T, Knoll G: Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. J Immunother Cancer 2016; 4: 64","DOI":"10.1186\/s40425-016-0171-8"},{"key":"10.3238\/arztebl.2019.0119_ref157","doi-asserted-by":"crossref","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al.: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 2017; 389: 2492\u2013502","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"10.3238\/arztebl.2019.0119_ref158","doi-asserted-by":"crossref","unstructured":"Heppt MV, Schlaak M, Eigentler TK, et al.: Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. Ann Oncol 2017; 28: 3104\u20136","DOI":"10.1093\/annonc\/mdx538"},{"key":"10.3238\/arztebl.2019.0119_ref159","doi-asserted-by":"crossref","unstructured":"Gay CL, Bosch RJ, Ritz J, et al.: Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J Infect Dis 2017; 215: 1725\u201333","DOI":"10.1093\/infdis\/jix191"},{"key":"10.3238\/arztebl.2019.0119_ref160","doi-asserted-by":"crossref","unstructured":"Knauss S, Ginesta Roque L, H\u00fchnchen P, Heinzerling L, B\u00f6hmerle W, Endres M: [Neurological side effects of checkpoint inhibitors]. Nervenarzt 2018; doi: 10.1007\/s00115\u2013018\u20130571\u20138","DOI":"10.1007\/s00115-018-0571-8"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T21:22:59Z","timestamp":1662931379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":160,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2019.0119","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]}}}